

INVITED SPEAKERS

THE HISTORY OF PAPILLOMAVIRUS RESEARCH

Stina Syrjänen¹, Kari Syrjänen²

¹Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Turku, Finland

²Department of Oncology & Radiotherapy, Turku University Hospital, Turku, Finland

Address for correspondence: S. Syrjänen, Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, FIN-20520 Turku, Finland. E-mail: stina.syrjanen@utu.fi

Key words: HPV, papilloma, cancer, condyloma, warts

INTRODUCTION

The present-day understanding of papillomavirus (HPV) research and clinical practice is a result of a long history of hard work consisting of important contributions of a countless number of past and present scientists. PV research has an interesting dual type of the past history; 1. basic virological data emerging from the animal experiments during the first half of last century, and 2. an increasing awareness of these viruses as a significant cause of human diseases emerging from the late 1970's.

Here we present milestones of the of HPV research in chronological list (Tables 1, 2 and 3). Like always, this type of listing represents the personal preferences of the authors, and the missing of someone's name in the list by no means signify the lack of importance of his/her work. The major focus of the listing is in the studies on HPVs, and the historical data on animal PVs are listed only when having immediate implications in understanding of the human disease. During the past several decades, several excellent reviews have been written on the history of papilloma-virus research (1–10).

OBSERVATIONS MADE BEFORE 1970

Genital warts were well known to physicians of the ancient world, at least from the time of Hippocrates (460–377 B.C.). Since those days, the term condyloma (a word of Greek origin) has been used for genital warts meaning “a round swelling around the anus”. At the end of the 19th century, the genital wart has been called condyloma accuminatum, “a pointed condyloma” (8). Since Antiquity, condylomata accuminata have been linked with sexual behavior, being particularly common in the anal region of homosexual males.

Also the skin warts have been known since the Roman Era. At the beginning of the 1st century A.D., Celsus described three

morphologically distinct types of cutaneous warts. These included 1. acrochordon, which was encountered exclusively in children and frequently underwent spontaneous resolution, 2. thymion, which was a papillomatous and highly vascular lesion, and 3. myrmecia, currently known as plantar warts.

In the virological point of view, nothing dramatic took place until the early 20th century. However, an important report from the 19th century deserves to be cited here. This document was published by an Italian physician, Rigoni-Stern in 1842, who analysed the certificates of death due to cancer in Verona during the period 1760–1839 (11). He found that deaths due to cancer of the uterus were very rare among virgins and nuns, as contrasted to married women and widows, among whom the disease was quite common in those days. Thus, he was the first to link cervical cancer with the sexual contacts.

It took another 50 years, however, until the infectious nature of cutaneous warts was reported by Payne (1891) and Jadassohn (1896) (12,13). This contagious mode of transmission was confirmed also for genital condylomas some 10 years later, when Heidingsfield described a prostitute, who had acquired condyloma lesions in her tongue as a result of oral sex (14). Only a few years later, the viral etiology of these lesions was demonstrated by Ciuffo in 1907, who used a cell filtrate of a common wart to transfer the infection (15). Human wart virus was later associated with genital (16) and laryngeal (17) warts. Ullman also claimed to have produced a papilloma of the vagina of a bitch upon inoculation with extract of laryngeal papilloma, but Findlay (18) was unable to confirm this finding. It took some 40 more years, however, before HPV was isolated as a microcrystalline form by Strauss et al. (19). During the subsequent twenty years, it was believed that all different manifestations of warts, both cutaneous and genital, were caused by a single type of the virus known as the human wart virus.

During this period of slow progress with understanding the clinical disease, some important breakthroughs were made in experimental animal studies. Shope and Hurst in 1933 were the first to describe a skin papilloma in wild, North American cottontail rabbits (20). These cutaneous papillomas could be

Table 1. Key discoveries signifying milestones in HPV research before 1970

Year	Author	Discovery
460-377 B.C.	Hippocrates	The name condyloma endowed to genital warts
25 A.D.	Celsus	Three types of skin warts: acrochordon, thymion, myrmecia
1842	Rigoni-Stern	"Venereal" nature of cervical cancer: rare in virgins and nuns
1891	Payne	Infectious nature of common warts
1901	Heidingsfield	Oral condylomas: a sign of illicit sex
1907	Ciuffo	Demonstration of the viral nature of skin warts
1923	Ullman	Demonstration of the viral nature of laryngeal papillomas
1933	Shope & Hurst	Isolation and characterization of cotton-tail rabbit papillomavirus (CRPV)
1935	Rous & Beard	Development of rabbit skin carcinomas due to synergistic actions between CRPV and chemical carcinogens
1938	Kidd & Rous	
1944	Friedewald & Rous	
1949	Parson and Kidd	Natural history of rabbits oral papillomas
1949	Ayre & Ayre	Halo cells in cervical carcinogenesis
1949	Strauss et al.	HPV particles in skin warts on EM
1950	Syverton et al.	Papilloma-to-carcinoma sequence in cottontail rabbits
1951	Olson et al.	Equine sarcoids caused by an agent of bovine papilloma
1954	Barrett & Silbar	Genital warts shown to be an STD
1956	Koss & Durfee	The concept of koilocytosis in PAP smears and cervical biopsies
1957	Jablonska et al.	Revival of epidermodysplasia verruciformis as a viral disease
1961	Ito & Evans	Induction of papillomas in domestic rabbits by CRPV
1965	Crawford; Klug & Finch	Structural and molecular characterization (mw) of papillomavirus DNA extracted from skin warts
1962	Melnick	Human Papova virus group
1967	Rowson & Mahy	
1968	Dunn & Ogilvie	EM demonstration of HPV particles in genital warts
1969	Almeida et al.	

Table 2. Key discoveries signifying milestones in HPV research during the 1970's

Year	Author	Discovery
1972-75	Pyrhönen et al.	Preliminary studies on antibody response to cutaneous and genital warts
1974	zur Hausen	HPV types differ in plantar and genital warts
1975-76	zur Hausen	Hypothesis presented on HPV as a potential cause of cervical cancer
1976	Gissmann & zur Hausen	Diversity of papillomavirus types
1977	Gissmann et al.	
1977	Orth et al.	
1976	Meisels et al.	Description of koilocytotic atypia as a sign of HPV in flat lesions of the uterine cervix
1977	Purola & Savia	
1978	Pyrhönen et al.	Wart virus antibodies detected in dogs, pigs and cattle
1978	Della Torre et al.	Demonstration of HPV particles in dysplastic lesions of the cervix on EM
1979	Hills & Lavery	
1978	Orth et al.	Specific HPV types in EV-derived skin carcinomas
1978-80	Quick et al.	Classical works on laryngeal papillomas, their atypia and association with HPVs
1979	Syrjänen, K.	Koilocytotic cells in invasive cervical cancer
1979	Law et al.	Gene cloning and hybridization under non-stringent conditions in HPV research
1979	Syrjänen, K.	HPV-suggestive changes in bronchial squamous cell cancer
1979	zur Hausen & Coggin	System for HPV classification

induced in both wild cottontail rabbits and in domestic rabbits using either purified or filtered homogenates of the tumours. In subsequent experiments, these authors showed that the disease was not transmitted among the domestic rabbits but readily from the wild rabbits to domestic rabbits (Cottontail rabbit papilloma-virus, CRPV) (20).

These primary observations were followed by a period of intense experimentation with this new papilloma model, conducted particularly by Peyton Rous and his colleagues between 1935–1944 (21–23). They convincingly demonstrated the importance of synergistic actions between CRPV and chemical carcinogens in the malignant transformation of the benign cutaneous papil-

Table 3. Key discoveries signifying milestones in HPV research since 1980 up to now

Year	Author	Discovery
1980	Gissmann & zur Hausen	Characterization of HPV-6 from a condyloma accuminatum lesion
1981	de Villiers	Cloning of HPV 6 in bacterial vectors
1982	Gissmann et al.	Cloning and characterization of HPV-11 from a laryngeal papilloma
1981	Syrjänen et al.	The first prospective follow-up study for cervical HPV infections initiated
1982	Syrjänen et al.	HPV involvement in squamous cell papilloma and cancer of the oesophagus
1983	Syrjänen et al.	HPV in inverted papillomas of the nasal cavity/paranasal sinuses
1983	Dürst et al.	Characterization of HPV-16 in cervical cancer biopsies
1982	Jenson et al.	HPV involvement in oral squamous cell lesions (benign & malignant)
1983	Syrjänen, S. et al.	
1984	Boshart et al.	Characterization of HPV-18 DNA in cervical cancer biopsies
1985	Kreider	Condyloma-type lesions induced by HPV-11 keratinocytes grafted in nude mice
1985	Beckman et al. Gupta et al.	<i>In situ</i> hybridization in cervical biopsies
1986	Lörincz et al.	Characterization of HPV-31
1986	Beaudenon et al.	Characterization of HPV-33
1986	Yasumoto et al.	Malignant transformation of NIH3T3 cells by HPV-16 DNA
1987	Pirisi et al. Dürst et al.	Immortalization of human keratinocytes by HPV-16 DNA
1988	Laimins et al.	Organotypic raft culture as an <i>in vitro</i> model in HPV research
1989	Dyson et al.	HPV E7 binding with Rb protein
1990	Werness et al.	HPV E6 binding with p53 protein
1992	Kirnbauer et al.	Production of virus-like particles by L1 and L2 self assembly
2006	Merck; GSK	FDA licensed a quadrivalent HPV vaccine

lomas. Experiments on these lines were continued by Syverton, who accurately described the papilloma-to-carcinoma sequence in both the domestic and cottontail rabbits (24). In 1943, Parson and Kidd published their milestone study where they showed that oral papillomatosis of rabbits is a viral disease and the oral papillomavirus was distinct from the skin papilloma virus (25). They also found that virus may somehow pass from the mothers to the young during the period of suckling and this in turn brought up the possibility that the virus might lie latent in the mouth of normal rabbits until favorable circumstances (injury or irritation) (25). The data of that paper are still actual and no similar natural history studies on oral papillomas in humans exist even today.

Since the early 1950's, increasing attention was paid to papillomavirus-induced tumours in domestic animals as well. Equine sarcoids are the most frequent spontaneously occurring tumours in horses. These connective tissue tumours usually do not metastasize but they may be locally invasive and capable of recurring even after a radical surgical excision. The etiological role of Bovine papillomavirus (BPV) was first suggested by the transmission experiments of Olson and Cook (26), the agent having been confirmed as BPV1 and BPV2 by other workers later.

Despite the persistent ancient belief that genital warts are linked with sexual habits, it was not until 1954, when the sexual transmission of genital condylomata accuminata was firmly established (27). These authors examined young American soldiers returning from the Korean war. After having had sexual intercourse with the local prostitutes in Korea, they transmitted the disease to their sexual partners in the U.S., who usually developed genital condylomas after 4 to 6 weeks of incubation period. Since its original description, the sexual mode of HPV transmission has been firmly established.

The 1950's also witnessed the appearance of two important papers giving cytological descriptions of genital HPV infections. In 1949, Ayre et al. described the morphology of halo cells in PAP smears and cervical biopsies, calling them as a precancer cell complex (28). One of their patients subsequently developed a carcinoma *in situ* (CIS) lesion, and the authors renamed this cytological abnormality as a "nearocarcinoma" in 1951. While studying the cytological smears taken during a pilot screening program, Koss and Durfee could confirm Ayre's discovery. They published their classical paper in 1956, giving this cellular abnormality a new name: koilocytotic atypia (29). The intriguing history of these early steps in describing the cytopathology of cervical cancer precursors was thoroughly revisited by Koss himself (30). The author admits, however, that the viral etiology of the koilocytotic atypia was not suspected in 1956, although the wart-like epithelial changes pointed to that direction (30). This same decade also saw the revival of interest in yet another clinical entity described in 1922 by Lewandowski and Lutz (31) as epidermodysplasia verruciformis (EV), when Jablonska published her classical paper on this subject in 1957 (32).

DNA or viral particles extracted from cottontail rabbit papillomas were shown to induce papillomas by Ito and Evans in 1961 (33). It still took a number of years until the genome of this CRPV was fully characterized. With the developing research techniques in 1960's, also human wart virus attracted new interest among virologists. In 1965, two groups (34, 35) characterized the structure and molecular weight of papillomavirus DNA extracted from skin warts. Finally, towards the end of 1960's, viral particles were finally demonstrated by electron microscopy also in genital warts (36, 37). Because of the fact that this virus was morphologically identical with the particles found in skin warts, it was believed

that both genital and skin warts are due to a single wart virus. By that time, this virus was included as a member in Human Papovavirus family (38, 39).

DISCOVERIES MADE IN THE 1970'S

The 1970's witnessed a number of major breakthroughs in many aspects of HPV research, representing both clinical discoveries and those made by basic scientists, the key discoveries being summarized in Table 2. The onset of the 1970's was heralded by the emerging data on serological response to human wart viruses. The pioneering observations of a Finnish virologist, Pyrhönen dating back to the early 1970's have received far too little attention (40–43). The authors detected measurable antibodies against pooled, homogenized wart tissue in 92% of the women and 75% of the males aging between 15–19 years. Important was also their observation on a roughly inverse correlation between the number and duration of skin warts and the antibody levels. While studying the patients with SLE, who showed HPV antibodies less frequently than their immunocompetent counterparts, the authors concluded that this lack of humoral response to HPV might explain the increased frequency of warts in SLE patients. They also speculated the antigenic relatedness between the HPVs in the genital and skin warts, as suggested by the less frequent occurrence of HPV antibodies in genital wart patients. While detecting measurable HPV antibodies in students reporting never having had visible wart lesions, the authors made the assumption that subclinical HPV infections must be quite common (43). They also concluded that there must be more than one HPV type.

HPV research of today owes much to one of the pioneers in the field, Dr. Harald zur Hausen, who turned his interest on HPV in the early 1970's. In the first of his classical series of 4 works from 1974–1976, attempting to detect virus specific DNA in human tumors, he completed nucleic acid hybridizations with complementary RNA of human wart virus (44). It became evident that different viruses are responsible for cutaneous common warts and genital warts. During the same period, he formulated his hypothesis on HPV as an etiological agent of cervical cancer (45, 46). In a series of studies from 1976–77, zur Hausen and his coworkers as well as Gerard Orth's group in Paris, established the plurality of HPVs, by disclosing the first 4 HPV types in cutaneous warts, numbered as HPV 1–4 (47–49). Also serological evidence was soon provided to support this plurality, because there seemed to be no link between HPV 1–4 and the HPV type (to be characterized) in condylomata accuminata, laryngeal papillomas or any of the malignant tumors tested (50).

From the clinical point of view, a major breakthrough was provided by two reports appearing in two subsequent issues (Nov-Dec & Jan-Feb) of *Acta Cytologica* in 1976 and 1977 (51, 52) by describing koilocytotic cells in cervical Papanicolaou (PAP) smears derived from flat epithelial lesions, frequently associated with cervical precancer lesions. In addition to characteristic koilocytes, these authors accurately described two other types of cells regularly exfoliating from genital condylomas; dyskeratotic superficial cells, and “condylomatous” intermediate cells (51, 52). It was soon realised that by observing the cytopathic effects of a virus on light microscopy, one could probably “see”

the evidence for an etiological agent of cervical cancer and its precursor lesions.

Della Torre and her colleagues as well as Hills & Lavery were the first to detect viral particles within the nuclei of koilocytes (53, 54) which were identical to those described in condylomata accuminata (36, 37), and in skin warts (19). This confirmed that also these flat and endophytic epithelial lesions of the genital tract are manifestations of an HPV infection, although distinct from the classical condyloma accuminatum in morphological appearance. This circuit was closed in 1979, when a case of invasive cervical squamous cell carcinoma was described with abundant koilocytes (55).

In 1978, two new HPV types associated with EV lesions were discovered by Orth and his group paving the way to subsequent detection of a large number of so called “EV-specific” HPV types recognized today (56).

In parallel with the incited interest in HPV lesions of the genital tract and skin, the suspected HPV origin of two additional lesions was confirmed; first with the juvenile-onset laryngeal papillomas and later with the adult-onset papillomas. Quick and coworkers described epithelial atypia in these lesions, with possible implications in their known risk for malignant transformation (57–59). Soon, conclusive clinical and virological evidence on similarities between genital condylomas and laryngeal papillomas was provided (59). Within the next two years, HPV involvement in laryngeal and esophageal squamous cell carcinomas was suggested by us, based on morphological features and detection of HPV antigens by immunohistochemistry (IHC) (60–62).

Before the introduction of DNA technology into general use, morphology, TEM and IHC were the means to provide evidence for the possible HPV involvement in genital and extra-genital squamous cell lesions. With these methods, we described koilocytotic cells and other morphological evidence (confirmed by IHC) suggestive of HPV involvement in bronchial squamous cell carcinomas (63) paving the way to a novel thinking about the potential HPV etiology of human squamous cell carcinomas at mucosal sites other than the genital tract, larynx or skin.

The decade was closed by an introduction of a unanimously agreed classification of PVs, based on the decisions of the first Workshop on papillomaviruses (64). This first classification was based exclusively on the sequence homology between the different PV isolates. Accordingly, viral DNA isolates are first classified according to their host species (HPV, BPV, CRPV, etc.) (see ref. 65), and within one species, according to their sequence homology: if there is less than 50% cross-hybridization with the known PV types when tested by re-association kinetics in the liquid phase, the viral DNA was assigned a new type. This classification prevailed until the early 1990's, when revised and finally PVs were classified as a taxonomic family of their own in 2004 (66).

INCREASING SPEED OF PROGRESS SINCE 1980

The 1980's witnessed a remarkable and dramatic progress in all areas of PV research mostly because of the development of molecular cloning and related techniques. This speed is well illustrated by the rapid discovery, cloning and characterization of an ever growing number of different HPV types, for which there is no end visible today. This development was started in 1980 by

Gissmann and zur Hausen, who isolated and characterized a new virus, which proved to be the etiological agent of classical genital warts and was designated as HPV-6 (67). Characterization of the first of these genital HPV types led to isolation of its closest relative from laryngeal papilloma receiving the label HPV-11 (68). At that time, all attempts to detect homologous DNA in laryngeal squamous cell carcinomas failed, however (68).

One of the absolute highlights of the early 1980's was the isolation and characterization of a new HPV type from cervical cancer, which subsequently has proved to be the single most important HPV type of them all, namely HPV-16, by Dürst and his colleagues in 1983 (69). While tested in a series of biopsies from cervical, vulvar, and penile cancer, >60% of cervical cancer samples were found to hybridize with HPV-16 DNA, the corresponding figures for vulvar and penile cancer being 28.6% and 25%, respectively. In contrast, practically none of the benign condyloma lesions were shown to contain HPV-16 DNA, which led the authors to suggest that HPV-16 is an HPV type characteristic to malignant squamous cell lesions of the genital tract.

In 1984, HPV-18 was isolated and characterized from cervical carcinoma (70). Importantly, HPV-18 DNA was also found in several cell lines derived from cervical cancer, including HeLa, KB and C4-1 lines (70). In 1986 Löhrincz and coworkers isolated HPV-31 (71), and HPV type 33 was molecularly cloned and characterized by the French group in the same year (72).

Although it may sound egocentric to include a number of one's own contributions in the list like this, the authors feel it justified to mention October 1981, the starting point of which probably is the most significant contribution of us to HPV research; the first prospective follow-up (cohort) study of women with HPV infection in the lower genital tract. By 1985, we had established that the natural history of cervical HPV lesions was identical with that of classical CIN lesions. In the same year, the inherent potential of HPV-16 and HPV-18 lesions to progress to invasive cancer was firmly established (73). Also the first epidemiological study on risk factors of HPV appeared at the same time, confirming the early onset of sexual activity, number of sexual partners, contraception mode as well as smoking among the key risk factors of HPV infections (74).

At the same time the authors did not lose their interest in exploring the potential HPV etiology of squamous cell tumours at other anatomical sites. This search led to description of such evidence in two distinct entities, squamous cell papilloma and carcinoma of the oesophagus in 1982 (75), followed a year afterwards by yet another squamous cell lesion, inverted papilloma of the nasal cavity/paranasal sinuses (76). The latter represent relatively rare tumours but have clinical importance due to their frequent tendency for recurrence (known before any evidence for HPV), and a small but definite risk for malignant transformation.

The same period witnessed extension of HPV research into yet another group of squamous cell lesions, subsequently gained a substantial clinical importance, i.e., the first evidence on HPV involvement in benign (77), and malignant (78) squamous cell tumours of the oral mucosa. The authors well remember that at that time, it was extremely difficult to get the reports on such a new idea (a potential etiological agent of oral cancer) accepted in any journals of oral medicine, which resulted in a marked delay in the publication of these studies (78,79). It was readily apparent that signs of HPV were found in oral condylomas, oral common warts

and focal epithelial hyperplasia (FEH) lesions (78, 79). Evidence was also provided, for the first time, that HPV may be involved in oral squamous cell carcinomas as well.

The mid 1980's also brought significant achievements in the methodological development of HPV research. Undoubtedly, two events on these lines deserve to be listed here: 1. the description of so called Kreider model, and 2. development of different hybridization methods. Kreider et al. in 1985 made experiments, where they succeeded in inducing epithelial changes consistent with condyloma accuminatum in epithelial cells derived from normal human uterine cervix after exposure to HPV-11 from a condyloma accuminatum lesion (80). This was the first demonstration of a morphological transformation of human tissues with an HPV under controlled, experimental conditions. The only disadvantage of the model is the failure of the grafted epithelium to support the replication of the oncogenic HPV types, e.g. HPV-16 and 18.

In parallel with the advances made in technology, also the basic understanding of the mechanisms how PVs induce malignant transformation did substantially increase through the innovative experiments, meritorious enough to be cited here. In 1986, Yasumoto and his coworkers described the transformation of a rodent cell line (NIH3T3) by HPV-16 (81). Using a recombinant HPV-16 DNA (pSHPV16d), which contains a head-to-tail dimer of the full-length HPV-16 genome, they could induce morphologic transformation, and indeed, the transformed cells proved to be tumorigenic in nude mice. Subsequently, the transformation of NIH3T3 cells has provided a useful model for analyzing the functions of HPV-16.

At least equally important are the two reports from 1987 (82, 83), where human keratinocytes and fibroblasts isolated from foreskin were transformed by transfection with recombinant HPV-16 DNA. The transformed cells exhibited an extended (fibroblasts) or indefinite (keratinocytes) life-span compared with that of normal controls. Such immortalized cell lines represent an unique system to study the interaction of HPV with its natural target cell *in vitro* (83).

Yet another technical innovation, albeit not an original development, was made in the late 1980's, when the organotypic raft culture was adopted in HPV research in Dr. Laimins' laboratory (84). Using a cell culture system for keratinocytes which allows stratification and production of differentiation-specific keratins, the authors examined the effects of HPV-16 on the differentiation capabilities of human epithelial cells. The histological abnormalities induced by HPV-16 closely resembled those seen in CIN lesions (84).

While approaching the 1990's, two key discoveries in the basic HPV research absolutely deserve their place in the list, because significantly contributing to our understanding about the basic mechanisms of virus-host cell interactions. Prompted by the previous observations that the Rb1 (retinoblastoma susceptibility) gene product, p105-RB, forms stable complexes with the oncoproteins of the adenovirus E1A proteins and the SV40 large T antigen, Dyson and coworkers in 1989 demonstrated that the E7 oncoprotein of HPV-16 can form similar complexes with p105-Rb (85). While a similar mechanisms in transformation was used by these three DNA viruses, the findings strongly implicated Rb-binding as a possible step in HPV-associated carcinogenesis (85).

This discovery was followed by a logical approach to explore, whether another tumour suppressor gene, p53, and its protein

product will bind to yet another oncoproteins of HPVs. Accordingly, Werness et al. in the same year (86), showed that the E6 protein of HPV-16 is capable of binding to the cellular p53 protein. Because of the fact that the wild-type p53 protein also forms complexes with the SV40 large T antigen and the E1B 55-kD protein of adenovirus type 5, an analogy was established between E7-Rb and E6-p53 complexing. Undoubtedly, this was a strong evidence in favor of the concept that HPVs, adenoviruses, and SV40 utilize similar cellular pathways in their transformation (86). Since these experiments, more than twenty human proteins have been identified interacting with either HPV-16 E6 or E7 proteins.

The closer we approach the present day, the more difficult it becomes to name the key discoveries on PV research. This is because of the fact that the literature is crowded by almost weekly reports on carefully conducted experiments, penetrating piece by piece into the secrets of HPVs and their interactions with the host cell machinery. However, important as they might be, the final significance of these newly reported data remains to be fully appreciated only after a few years.

As the last account in this long chain of discoveries, the authors selected just one from the 1990's, which already by now has opened completely new visions into at least two important areas of HPV research: serology and vaccination. This of course is the description of the technique how to make virus-like particles (VLP) *in vitro*, by Kirnbauer and his associates (87). These authors succeeded in expressing the L1 major capsid proteins of BPV1 and HPV-16 in insect cells using a baculovirus vector and analyzed their conformation and immunogenicity. The L1 proteins were expressed at high levels and, surprisingly, assembled into structures that closely resembled PV virions (87). These self-assembled BPV L1 VLPs mimicked intact BPV virions, e.g. being capable of inducing neutralizing antisera in rabbits. Thus, the L1 protein seemed to have an intrinsic capacity to assemble into empty capsid-like structures with immunogenicity similar to that of infectious virions. This novel L1 VLP preparation was immediately recognized as a potential candidate for serological tests to measure antibodies to conformational virion epitopes, as well as for a vaccine to prevent HPV infections (87). Subsequent studies on these lines have resulted in the development of the first-generation prophylactic vaccines against HPV-6, -11, -16, -18 (Gardasil®, Merck) or against HPV-16 and HPV-18 (Cervarix®, GSK).

With the current understanding of the role of HPVs in human carcinogenesis and viewing the WHO incidence- and mortality statistics of 15 major malignancies worldwide, it can be estimated that HPVs might be involved in the development of at least 5% of all human malignancies. This fact alone should justify the distribution of updated information on HPVs as a cause of major human pathology not only to gynecologists and dermato-venereologists, but to specialists in many other fields of medicine as well.

REFERENCES

1. Syverton JT, Dascomb HE, Wells EB, Koomen J Jr, Berry GP. The virus-induced rabbit papilloma-to-carcinoma sequence. II. Carcinomas in the natural host, the cottontail rabbit. *Cancer Res.* 1950 Jul;10(7):440-4.
2. Bäfverstedt B. Condylomata acuminata- past and present. *Acta Derm Venereol.* 1967;47(5):376-81.
3. Grodzicker T, Hopkins N. Origins of contemporary DNA tumor virus research. In: Tooze J, editor. *DNA tumor viruses: molecular biology of tumor viruses.* Cold Spring Harbor: Cold Spring Harbor Laboratory; 1981.
4. Oriel JD. Pathogenesis. In: Von Krogh G, Rylander E, editors. *GPVI. Genitoanal papilloma virus infection: a survey for the clinician.* Karlstad: Conpharm AB; 1989.
5. Lancaster WD, Olson C. Animal papillomaviruses. *Microbiol Rev.* 1982 Jun;46(2):191-207.
6. Gross L. Papillomas, warts, and related neoplasms in rabbits, dogs, horses, cattle, hamsters and in man. *Oncogenic Viruses.* Volume 2. 3rd ed. Oxford: Pergamon Press; 1983.
7. Orth G. Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. *Ciba Found Symp.* 1986;120:157-74.
8. Oriel JD. Pathogenesis. In: Von Krogh G, Rylander E, editors. *GPVI. Genitoanal papillomavirus infection: a survey for the clinician.* Karlstad: Conpharm AB; 1989.
9. Zur Hausen H, de Villiers EM. Human papillomaviruses. *Annu Rev Microbiol.* 1994;48:427-47.
10. Lowy DR. History of papillomavirus research. In: Campo MS, editor. *Papillomavirus research: from natural history to vaccines and beyond.* Hethersett: Caister Academic Press; 2006. p. 13-28.
11. Rigoni-Stern A. Statistics relating to cancerous diseases. *Gior Servire Progr Pathol Therap.* 1842;2:507-17. (In Italian.)
12. Payne J. On the contagious rise of common warts. *Br J Dermatol.* 1891;3:185.
13. Adassohn J. Are common warts contagious? *Verhandel D Deutsch Dem Gesellsch.* 1896;5:497-512. (In German.)
14. Heidingsfield ML. Flat acuminate warts. *J Cutan Genitourin Dis.* 1901;19:226-34.
15. Ciuffo G. Positive transfer with a filtrate of the common wart. *Gior Ital D Mal Ven.* 1907;48:12-7. (In Italian.)
16. Serra A. Studies on the virus of warts, papilloma and acuminate warts. *Giornale Italiano delle Malattie Veneree e delle Pelle.* 1924;65:1808-14. (In Italian.)
17. Ullman EV. On the aetiology of the laryngeal papilloma. *Acta Otolaryngol.* 1923;5:317-34.
18. Findlay GM. Warts. In: *A system of bacteriology in relation to medicine.* Volume 7, Chapter XVIII. London: Great Britain Medical Research Council; 1930. p. 252-258.
19. Strauss MJ, Shaw EW, Bunting HL, Melnick J. Crystalline virus-like particles from skin papillomas characterized by intranuclear inclusion bodies. *Proc Soc Exp Biol Med.* 1949 Oct;72(1):46-50.
20. Shope RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on the histopathology. *J Exp Med.* 1933;58:607-24.
21. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (Shope). *J Exp Med.* 1935;62:523-48.
22. Rous P, Kidd JG. The carcinogenic effect of a papilloma virus on the tarred skin of rabbits. I. Description of the phenomenon. *J Exp Med.* 1938;67:399-422.
23. Rous P, Friedewald WF. The effect of chemical carcinogens on virus-induced rabbit papillomas. *J Exp Med.* 1944;79:511-38.
24. Syverton JT, Dascomb HE, Wells EB, Koomen J Jr, Berry GP. The virus-induced rabbit papilloma-to-carcinoma sequence. II. Carcinomas in the natural host, the cottontail rabbit. *Cancer Res.* 1950 Jul;10(7):440-4.
25. Parsons RJ, Kidd JG. Oral papillomatosis of rabbits: a virus disease. *J Exp Med.* 1943;77:233-50.
26. Olson C Jr, Cook RH. Cutaneous sarcoma-like lesions of the horse caused by the agent of bovine papilloma. *Proc Soc Exp Biol Med.* 1951 Jun;77(2):281-4.
27. Barrett TJ, Silbar JD, McGinley JP. Genital warts- a venereal disease. *J Am Med Assoc.* 1954 Jan 23;154(4):333-4.
28. Ayre JE, Ayre WB. Progression of pre-cancer stage to early carcinoma of cervix within one year; combined cytologic and histologic study with report of a case. *Am J Clin Pathol.* 1949 Aug;19(8):770-8.
29. Koss LG, Durfee GR. Unusual patterns of squamous epithelium of the uterine cervix: cytologic and pathologic study of koilocytotic atypia. *Ann NY Acad Sci.* 1956 Mar 30;63(6):1245-61.
30. Koss LG. Carcinogenesis in the uterine cervix and Human papilloma-virus infection. In: Syrjänen K, Gissmann L, Koss LG, editors. *Papillomaviruses and human disease.* Heidelberg: Springer-Verlag; 1987. p. 235-67.
31. Lewandowski T, Lutz W. A case of a hitherto undescribed skin disease (Epidermodysplasia verruciformis). *Arch Dermatol Syphilol.* 1922;141:193. (In German.)
32. Jablonska S, Milewski B. Information on epidermodysplasia verruciformis Lewandowsky-Lutz; positive results of auto- and heteroinoculation. *Dermatologica.* 1957 Jul;115(1):1-22. (In German.)

33. Ito Y, Evans CA. Induction of tumors in domestic rabbits with nucleic acid preparations from partially purified Shope papilloma virus and from extracts of papillomas of domestic and cottontail rabbits. *J Exp Med*. 1961;114:485-500.
34. Crawford LV. A study of human papilloma virus DNA. *J Mol Biol*. 1965 Sep;13(2):362-72.
35. Klug A, Finch JT. Structure of viruses of the papilloma polyoma type. I. Human wart virus. *J Mol Biol*. 1965 Feb;11:403-23.
36. Dunn AE, Ogilvie MM. Intracellular virus particles in human genital wart tissue observations on the ultrastructure of the epidermal layer. *J Ultrastr Res*. 1968 Feb;22(3):282-95.
37. Almeida JD, Oriel JD, Stannard LM. Characterization of the virus found in human genital warts. *Microbios*. 1969;3:225-32.
38. Melnick JL. Papova virus group. *Science*. 1962 Mar 30;135:1128-30.
39. Rowson KE, Mahy BW. Human papova (wart) virus. *Bacteriol Rev*. 1967 Jun;31(2):110-31.
40. Pyrhönen S, Penttinen K. Wart-virus antibodies and the prognosis of wart disease. *Lancet*. 1972 Dec 23;2(7791):1330-2.
41. Pyrhönen S, Johansson E. Regression of warts. An immunological study. *Lancet*. 1975 Mar 15;1(7907):592-6.
42. Pyrhönen S, Neuvonen E. The occurrence of human wart-virus antibodies in dogs, pigs, and cattle. *Arch Virol*. 1978;57(4):297-305.
43. Pyrhönen S. Human wart-virus antibodies in patients with genital and skin warts. *Acta Derm Venereol*. 1978;58(5):427-32.
44. Zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. Attempts to detect virus specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. *Int J Cancer*. 1974 May 15;13(5):650-6.
45. Zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. *Bibl Haematol*. 1975 Oct;(43):569-71.
46. Zur Hausen H. Condylomata acuminata and human genital cancer. *Cancer Res*. 1976 Feb;36(2 pt 2):794.
47. Gissmann L, zur Hausen HZ. Human papilloma virus DNA: physical mapping and genetic heterogeneity. *Proc Natl Acad Sci USA*. 1976 Apr;73(4):1310-3.
48. Gissmann L, Pfister H, zur Hausen H. Human papilloma viruses (HPV): characterization of four different isolates. *Virology*. 1977 Feb;76(2):569-80.
49. Orth G, Favre M, Croissant O. Characterization of a new type of human papillomavirus that causes skin warts. *J Virol*. 1977 Oct;24(1):108-20.
50. Pfister H, zur Hausen H. Seroepidemiological studies of human papilloma virus (HPV 1) infections. *Int J Cancer*. 1978 Feb 15;21(2):161-65.
51. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. *Acta Cytol*. 1976 Nov-Dec;20(6):505-9.
52. Puroila E, Savia E. Cytology of gynecologic condyloma acuminatum. *Acta Cytol*. 1977 Jan-Feb;21(1):26-31.
53. Della Torre G, Pilotti S, de Palo G, Rilke F. Viral particles in cervical condylomatous lesions. *Tumori*. 1978 Oct 31;64(5):549-53.
54. Hills E, Laverty CR. Electron microscope detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. *Acta Cytol*. 1979 Jan-Feb;23(1):53-6.
55. Syrjänen KJ. Histological and cytological evidence of a condylomatous lesion in association with an invasive carcinoma of uterine cervix. *Arch Geschwulstforsch*. 1979;49(5):436-43.
56. Orth G, Jablonska S, Favre M, Croissant O, Jarzabek-Chorzelska M, Rzeska G. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. *Proc Natl Acad Sci USA*. 1978 Mar;75(3):1537-41.
57. Quick CA, Faras A, Krzysek R. The etiology of laryngeal papillomatosis. *Laryngoscope*. 1978 Nov;88(11):1789-95.
58. Quick CA, Foucar E, Dehner LP. Frequency and significance of epithelial atypia in laryngeal papillomatosis. *Laryngoscope*. 1979 Apr;89(4):550-60.
59. Quick CA, Watts SL, Krzysek RA, Faras AJ. Relationship between condylomata and laryngeal papillomata. Clinical and molecular virological evidence. *Ann Otol Rhinol Laryngol*. 1980 Sep-Oct;89(5 Pt 1):467-71.
60. Syrjänen KJ, Syrjänen SM. Histological evidence for the presence of condylomatous epithelial lesions in association with laryngeal squamous cell carcinoma. *ORL J Otorhinolaryngol Relat Spec*. 1981;43(4):181-94.
61. Syrjänen KJ, Syrjänen SM, Pyrhönen S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. *ORL J Otorhinolaryngol Relat Spec*. 1982;44(6):323-34.
62. Syrjänen KJ. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. *Arch Geschwulstforsch*. 1982;52(4):283-92.
63. Syrjänen KJ. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. *Respiration*. 1979;38(5):299-304.
64. Coggin J Jr, zur Hausen H. Workshop on papillomaviruses and cancer. *Cancer Res*. 1979;39:545-6.
65. Sundberg JP. Papillomavirus infections in animals. In: Syrjänen K, Gissmann L, Koss LG, editors. *Papillomaviruses and human disease*. Heidelberg: Springer-Verlag; 1987. p. 41-103.
66. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. *Virology*. 2004 Jun 20;324(1):17-27.
67. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts (*Condylomata acuminata*). *Int J Cancer*. 1980 May 15;25(5):605-9.
68. Gissmann L, Diehl V, Schultz-Coulon HJ, zur Hausen H. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. *J Virol*. 1982 Oct;44(1):393-400.
69. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. *Proc Natl Acad Sci USA*. 1983 Jun;80(12):3812-5.
70. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. *EMBO J*. 1984 May;3(5):1151-7.
71. Lorincz AT, Lancaster WD, Temple GF. Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. *J Virol*. 1986 Apr;58(1):225-9.
72. Beaudenon S, Kremsdorf D, Croissant O, Jablonska S, Wain-Hobson S, Orth G. A novel type of human papillomavirus associated with genital neoplasias. *Nature*. 1986 May 15-21;321(6067):246-9.
73. Syrjänen K, de Villiers EM, Saarikoski S, Castren O, Väyrynen M, Mäntytjärvi R, et al. Cervical papillomavirus infection progressing to invasive cancer in less than three years. *Lancet*. 1985 Mar 2;1(8427):510-1.
74. Syrjänen K, Väyrynen M, Castren O, Yliskoski M, Mäntytjärvi R, Pyrhönen S, et al. Sexual behaviour of women with human papillomavirus (HPV) lesions of the uterine cervix. *Br J Vener Dis*. 1984 Aug;60(4):243-8.
75. Syrjänen K, Pyrhönen S, Aukee S, Koskela E. Squamous cell papilloma of the esophagus: a tumour probably caused by human papillomavirus (HPV). *Diagn Histopathol*. 1982 Oct-Dec;5(4)291-6.
76. Syrjänen KJ, Pyrhönen S, Syrjänen SM. Evidence suggesting human papillomavirus (HPV) etiology for the squamous cell papilloma of the paranasal sinus. *Arch Geschwulstforsch*. 1983;53(1):77-82.
77. Jenson AB, Lancaster WD, Hartmann DP, Shaffer EL Jr. Frequency and distribution of papillomavirus structural antigens in verrucae, multiple papillomas, and condylomata of the oral cavity. *Am J Pathol*. 1982 May;107(2):212-8.
78. Syrjänen KJ, Pyrhönen S, Syrjänen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. *Brit J Oral Surg*. 1983 Jun;21(2):147-53.
79. Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. *Int J Oral Surg*. 1983 Dec;12(6):418-24.
80. Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, et al. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. *Nature*. 1985 Oct 17-23;317(6038):639-41.
81. Yasumoto S, Burkhardt AL, Doniger J, DiPaolo JA. Human papillomavirus type 16 DNA induced malignant transformation of NIH 3T3 cells. *J Virol*. 1986 Feb;57(2):572-7.
82. Pirijs L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. *J Virol*. 1987 Apr;61(4):1061-6.
83. Dürst M, Dzarlieva-Petrusevska RT, Boukamp P, Fusenig NE, Gissmann L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. *Oncogene*. 1987;1(3):251-6.
84. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. *Proc Natl Acad Sci USA*. 1988 Oct;85(19):7169-73.
85. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science*. 1989 Feb 17;243(4893):934-7.
86. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. *Science*. 1990 Apr 6;248(4951):76-9.
87. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc Natl Acad Sci USA*. 1992 Dec 15;89(24):12180-4.